DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jj2w94/renal_cell) has announced the addition of the "Renal Cell Carcinoma - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Renal Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Cell Carcinoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development: 35 of the 81 Companies Featured
- Acceleron Pharma, Inc.
- Advenchen Laboratories, LLC
- Altor BioScience Corporation
- Ambrx, Inc.
- Amgen Inc.
- Ampio Pharmaceuticals, Inc.
- Angiogene Pharmaceuticals Limited
- arGEN-X BV
- Argos Therapeutics, Inc.
- Astellas Pharma Inc.
- Bayer AG
- Beta Pharma, Inc.
- Bio-Cancer Treatment International Limited
- Biogenomics Limited
- Bionomics Limited
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- Caladrius Biosciences, Inc.
- Calithera Biosciences, Inc.
- Celldex Therapeutics, Inc.
- Celltrion, Inc.
- Cerulean Pharma, Inc.
- Chipscreen Biosciences Ltd
- Conkwest, Inc.
- CureTech Ltd.
- Cytune Pharma SAS
- Eisai Co., Ltd.
- Eli Lilly and Company
- Epirus Biopharmaceuticals, Inc.
- Exelixis, Inc.
- F. Hoffmann-La Roche Ltd.
- Genor BioPharma Co., Ltd.
- GenSpera, Inc.
- GlaxoSmithKline Plc
For more information visit http://www.researchandmarkets.com/research/jj2w94/renal_cell
